Chapter 193

It is a recombinant, nonglycosylated version of IL-1Ra that competitively inhibits both IL-1α and IL-1β activity at the IL-1 receptor.

• Rilanocept

• Canakinumab

• Etanercept

• Anakinra

Interleukin that is best understood for its ability, in combination with IL-12, for the induction of Th1 T-cell responses.

• IL-16

• IL-18

• IL-20

• IL-22

This is the fundamental cytokine for directing epidermal responses to injury and infection.

• IL-1

• IL-2

• IL-3

• IL-4

This is a fully human anti–IL-17A IgG1 κ monoclonal antibody for plaque psoriasis.

• Ixekizumab

• Brodalimumab

• Secukinumab

• Guselkumab

IgG1 κ human monoclonal antibody that targets IL-12p40

• Tildrakizumab

• Ustekinumab

• Risankizumab

• Infliximab

Most common adverse effect of EFGR inhibitors

• pustules

• vesicles

• plaques

• erythema

Monoclonal antibody that inhibits binding of IL-4 and IL-13

• Cetuximab

• Dupilumab

• Panitumumab

• Mogamulizumab

Th1 cytokine with antitumor activity produced by CD4+ lymphocytes in response to activation by antigen-presenting cells

• IL-2

• IL-4

• IL-6

• IL-8

Humanized monoclonal antibody, targeted at IL-6R

• Tocilizumab

• Brentuximab

• Denileukin difitox

• Risankizumab

Dose of brentuximab vedotin for mycosis fungoides

• 1.2 mg/kg once every 4 weeks

• 1.4 mg/kg once every 5 weeks

• 1.6 mg/kg once every 6 weeks

• 1.8 mg/kg once every 3 weeks